Quanterix Corporation Launches Pioneering p-Tau 205 and 212 Assays to Enhance Alzheimer's Research at AAIC 2025

Reuters

Jul 28

Quanterix Corporation Launches Pioneering p-Tau 205 and 212 Assays to Enhance Alzheimer's Research at AAIC 2025

Quanterix Corporation has announced the commercial launch of two novel phospho-tau assays, p-Tau 205 and p-Tau 212, aimed at advancing Alzheimer's research. These assays are designed to expand the company's portfolio of blood-based biomarkers for Alzheimer's disease and neurodegeneration. The launch coincides with Quanterix's participation at the Alzheimer's Association International Conference $(AAIC)$ 2025, where over 55 posters and presentations featuring data utilizing its Simoa® technology will be showcased. The assays, developed on the Simoa® platform, are available for use on the HD-X or SR-X instruments or through testing at Quanterix's Accelerator Lab. The introduction of these assays is part of Quanterix's efforts to provide support for earlier detection and personalized treatment approaches for Alzheimer's disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250728299738) on July 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2554306775"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554306775\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554306775?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-28 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554306775","market":"fut","top_or_hot":-1,"title":"Quanterix Corporation Launches Pioneering p-Tau 205 and 212 Assays to Enhance Alzheimer's Research at AAIC 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Quanterix Corporation Launches Pioneering p-Tau 205 and 212 Assays to Enhance Alzheimer's Research at AAIC 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Quanterix Corporation has announced the commercial launch of two novel phospho-tau assays, p-Tau 205 and p-Tau 212, aimed at advancing Alzheimer's research. These assays are designed to expand the company's portfolio of blood-based biomarkers for Alzheimer's disease and neurodegeneration. The launch coincides with Quanterix's participation at the Alzheimer's Association International Conference <a href=\"https://laohu8.com/S/AAIC\">$(AAIC)$</a> 2025, where over 55 posters and presentations featuring data utilizing its Simoa® technology will be showcased. The assays, developed on the Simoa® platform, are available for use on the HD-X or SR-X instruments or through testing at Quanterix's Accelerator Lab. The introduction of these assays is part of Quanterix's efforts to provide support for earlier detection and personalized treatment approaches for Alzheimer's disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250728299738) on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quanterix Corporation Launches Pioneering p-Tau 205 and 212 Assays to Enhance Alzheimer's Research at AAIC 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuanterix Corporation Launches Pioneering p-Tau 205 and 212 Assays to Enhance Alzheimer's Research at AAIC 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-28 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Quanterix Corporation Launches Pioneering p-Tau 205 and 212 Assays to Enhance Alzheimer's Research at AAIC 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Quanterix Corporation has announced the commercial launch of two novel phospho-tau assays, p-Tau 205 and p-Tau 212, aimed at advancing Alzheimer's research. These assays are designed to expand the company's portfolio of blood-based biomarkers for Alzheimer's disease and neurodegeneration. The launch coincides with Quanterix's participation at the Alzheimer's Association International Conference <a href=\"https://laohu8.com/S/AAIC\">$(AAIC)$</a> 2025, where over 55 posters and presentations featuring data utilizing its Simoa® technology will be showcased. The assays, developed on the Simoa® platform, are available for use on the HD-X or SR-X instruments or through testing at Quanterix's Accelerator Lab. The introduction of these assays is part of Quanterix's efforts to provide support for earlier detection and personalized treatment approaches for Alzheimer's disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250728299738) on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QTRX","symbol_name":"Quanterix Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDLbmHR25:1","article_id":"2554306775","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554306775","pubTimestamp":1753700460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Quanterix Corporation has announced the commercial launch of two novel phospho-tau assays, p-Tau 205 and p-Tau 212, aimed at advancing Alzheimer's research. These assays are designed to expand the company's portfolio of blood-based biomarkers for Alzheimer's disease and neurodegeneration. The launch coincides with Quanterix's participation at the Alzheimer's Association International Conference  2025, where over 55 posters and presentations featuring data utilizing its Simoa technology will be showcased. The assays, developed on the Simoa platform, are available for use on the HD-X or SR-X instruments or through testing at Quanterix's Accelerator Lab. The introduction of these assays is part of Quanterix's efforts to provide support for earlier detection and personalized treatment approaches for Alzheimer's disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QTRX":"Quanterix Corp","BK4121":"生命科学工具和服务"},"translate_title":"Quanterix Corporation在AAIC 2025上推出开创性的p-Tau 205和212检测以增强阿尔茨海默病研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QTRX":0.9},"content_text":"Quanterix Corporation Launches Pioneering p-Tau 205 and 212 Assays to Enhance Alzheimer's Research at AAIC 2025\n    \n\n        Quanterix Corporation has announced the commercial launch of two novel phospho-tau assays, p-Tau 205 and p-Tau 212, aimed at advancing Alzheimer's research. These assays are designed to expand the company's portfolio of blood-based biomarkers for Alzheimer's disease and neurodegeneration. The launch coincides with Quanterix's participation at the Alzheimer's Association International Conference $(AAIC)$ 2025, where over 55 posters and presentations featuring data utilizing its Simoa® technology will be showcased. The assays, developed on the Simoa® platform, are available for use on the HD-X or SR-X instruments or through testing at Quanterix's Accelerator Lab. The introduction of these assays is part of Quanterix's efforts to provide support for earlier detection and personalized treatment approaches for Alzheimer's disease.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250728299738) on July 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}